Praxis Precision Medicines, Inc. reported significant financial results for the third quarter of 2025, revealing a net loss of $73.9 million, compared to a net loss of $51.9 million for the same period in 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $214.4 million, up from $124.1 million in the prior year. The increase in losses is attributed primarily to a substantial rise in research and development expenses, which totaled $189.6 million for the nine-month period, compared to $96.1 million in 2024. The company's operating expenses for the third quarter reached $78.4 million, a 37% increase from $57.1 million in the previous year.
In terms of revenue, Praxis did not report any collaboration revenue for the third quarter or the nine months ended September 30, 2025, a decline from $0.3 million and $1.1 million, respectively, in the prior year. This decrease is linked to the completion of obligations under a collaboration agreement with UCB Biopharma, which was exercised in December 2024. The company’s total assets decreased to $396.4 million as of September 30, 2025, down from $483.1 million at the end of 2024, primarily due to a reduction in cash and cash equivalents, which fell to $149.5 million from $215.4 million.
Operationally, Praxis has been advancing its clinical-stage product candidates across its two proprietary platforms, Cerebrum™ and Solidus™. The company announced positive topline results for its ulixacaltamide program in October 2025, which is part of the Phase 3 Essential3 program for essential tremor. Additionally, the company is progressing with its vormatrigine and relutrigine programs, with several studies ongoing and positive results reported. As of September 30, 2025, Praxis had 21.2 million shares outstanding, an increase from 19.4 million shares at the end of 2024, reflecting ongoing capital-raising efforts.
Looking ahead, Praxis anticipates continued operating losses as it invests in research and development activities. The company expects its cash, cash equivalents, and marketable securities, totaling $389.2 million as of September 30, 2025, along with proceeds from a recent public offering, to be sufficient to fund operations into 2028. However, the company acknowledges the need for substantial additional funding to support its growth strategy, which includes advancing clinical trials, expanding its product pipeline, and establishing a commercialization infrastructure. The future viability of Praxis remains contingent on its ability to secure additional capital and successfully develop its product candidates.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines is a biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly epilepsy and movement disorders. Utilizing genetic insights, its platforms create targeted small molecules and antisense oligonucleotides. The company advances precision medicines through clinical trials, leveraging collaborations and proprietary technologies to address unmet needs in neurological conditions with high patient burden.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.